Immune development in early life - Immune development in early life

niversitair Medisch Centrum Utrecht0 个研究点目标入组 205 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Healthy term (37-42 weeks) newborns born in the hospital on maternal indication after an uncomplicated pregnancy and delivery
•- Diabetes group: Newborns from mothers with diabetes mellitus or diabetes gravidarum at risk for hypoglycaemia and who will routinely have several glucose controls in the first 24-48 hours after birth
•- Sepsis group: Newborns with a clinical diagnosed sepsis
•- PCOS group: Newborns from mothers with PCOS
•- CMV infection group: Preterm born children (AD<32 weeks) with a postnatal acquired CMV infection and matched controls with similar clinical and patient characteristics but without a CMV infection

•- Complications during pregnancy (HELLP, pre-ecmplampsia, infection) except for the pathological conditions under investigation
•- Smoking during pregnancy
•- Use of immune-modulating medication during pregnancy
•- Use of antibiotics by the mother in two weeks before delivery
•- Perinatal complications not related to inclusion criteria
•- Prematurity (GA<36 weeks) or dysmaturity (birth weight < -2 SD) except for the preterm born children in the CMV infected population or their controls
•- Immunological disorders like velocardiofacial syndrome, DiGeorge syndrome
•- Chromosomal disorders

发起方

niversitair Medisch Centrum Utrecht